Overall Interim Findings (Entire Study Population, 214Patients; Six-Week Analysis)

All 214 patients who switched to CREXONT (mean age 67.1±9.07 years):

Increased Daily "Good On" Time:

  • +3.33 hours when switching from IR CD/LD (n=156)
  • +3.20 hours when switching from IR CD/LD + COMT inhibitor (n=17)
  • +3.03 hours when switching from RYTARY (n=41)

     

Reduced Daily "Off" Time:

  • –3.20 hours when switching from IR CD/LD
  • –2.96 hours when switching from IR CD/LD + COMT inhibitor
  • –2.4 hours when switching from RYTARY

     

Improved MDS-UPDRS Total Scores

  • Improvements of –14.6, –9.9, and –10.0 points when switching from IR CD/LD, IR CD/LD + COMT inhibitor, and RYTARY, respectively — reductions of this magnitude reflect clinically meaningful gains in overall motor function

     

Subgroup Analysis: Additional Interim Findings in Patients Switching from RYTARY®

Among the 41 patients switching from RYTARY, CREXONT delivered particularly notable gains in symptom control:

  • Mean duration of continuous "Good On" intervals nearly doubled, increasing from 3.19 hours at baseline to 6.27 hours at Week 6, a 3.08-hour gain in uninterrupted symptom control
  • Mean daily motor fluctuations were meaningfully reduced, decreasing from 5.28 at baseline to 2.98 at Week 6, a 2.26 (42.80%) reduction in the average number of daily motor fluctuations